Bluejay Diagnostics (BJDX) Income from Continuing Operations (2020 - 2026)
Bluejay Diagnostics (BJDX) posted Income from Continuing Operations of 2019972.0 for Q1 2026, down 41.22% sequentially from 1430391.0 in Q4 2025, and down 5.79% YoY from 2144169.01 in Q1 2025.
Bluejay Diagnostics (BJDX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Bluejay Diagnostics has reported Income from Continuing Operations for 7 years, with the latest figure at 2019972.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 5.79% year-over-year to 2019972.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7021087.0 (up 12.69% YoY) and the FY2025 annual result came in at 18945019.0, down 11.06% from the prior year.
- Income from Continuing Operations fell to 2019972.0 in Q1 2026 per BJDX's latest filing, from 1430391.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1430391.0 in Q4 2025 and troughed at 3003688.0 in Q2 2023.
- A 5-year average of 2213688.0 and a median of 2135398.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 791.77% in 2022, then jumped 36.48% in 2024.
- Over 5 years, Income from Continuing Operations stood at 2490229.0 in 2022, then climbed by 2.39% to 2430672.0 in 2023, then rose by 12.15% to 2135398.0 in 2024, then surged by 33.02% to 1430391.0 in 2025, then plunged by 41.22% to 2019972.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2019972.0, 1430391.0, and 1604994.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Bluejay Diagnostics | 1.91 Mn | 1.91 Mn | - | -2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.40 Mn |
| Mar 31, 2026 | -2.02 Mn |
| Dec 31, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.60 Mn |
| Jun 30, 2025 | -1.97 Mn |
| Mar 31, 2025 | -1.91 Mn |
| Dec 31, 2024 | -2.14 Mn |
| Sep 30, 2024 | -1.49 Mn |
| Jun 30, 2024 | -2.51 Mn |
| Mar 31, 2024 | -2.44 Mn |
| Dec 31, 2023 | -2.43 Mn |
| Sep 30, 2023 | -2.35 Mn |
| Jun 30, 2023 | -3.00 Mn |
| Mar 31, 2023 | -2.72 Mn |
| Dec 31, 2022 | -2.49 Mn |
| Sep 30, 2022 | -2.91 Mn |
| Jun 30, 2022 | -2.13 Mn |
| Mar 31, 2022 | -2.10 Mn |
| Dec 31, 2021 | -1.34 Mn |
| Sep 30, 2021 | -1.69 Mn |